Harbor Capital Advisors’s Haemonetics HAE Stock Holding History

Harbor Capital Advisors’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13K	Sell	168 -4	-2%	-$257	﹤0.01%	938
2026 Q1	$10K	Sell	172 -20,459	-99%	-$1.33M	﹤0.01%	977
2025 Q4	$1.65M	Sell	20,631 -22,228	-52%	-$1.49M	0.13%	223
2025 Q3	$2.09M	Buy	42,859 +14,226	+50%	+$881K	0.16%	168
2025 Q2	$2.14M	Sell	28,633 -5,899	-17%	-$391K	0.09%	284
2025 Q1	$2.19M	Sell	34,532 -15,822	-31%	-$1.08M	0.1%	269
2024 Q4	$3.93M	Sell	50,354 -5,810	-10%	-$467K	0.17%	172
2024 Q3	$4.51M	Buy	56,164 +30,389	+118%	+$2.46M	0.2%	158
2024 Q2	$2.13M	Buy	25,775 +19,510	+311%	+$1.72M	0.16%	183
2024 Q1	$535K	Buy	+6,265	New	+$492K	0.07%	379

Other funds holding HAE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harbor Capital Advisors's HAE Position: Q2 2026 in Review

Harbor Capital Advisors reduced its Haemonetics (HAE) stake by 2.3% in Q2 2026, selling an estimated $257 and leaving 168 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #938.

Harbor Capital Advisors first reported a position in HAE in Q1 2024 and has held it in 10 quarters since. The position peaked at $4.51M in Q3 2024. 330 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

Harbor Capital Advisors held 168 shares of Haemonetics worth $13K as of Q2 2026.
Harbor Capital Advisors sold 4 Haemonetics shares in Q2 2026, an estimated $257.
Haemonetics made up ﹤0.01% of Harbor Capital Advisors's portfolio in Q2 2026, its #938 holding.
Harbor Capital Advisors first reported a position in Haemonetics in Q1 2024 and has held it in 10 quarters since.
Harbor Capital Advisors's Haemonetics position peaked at $4.51M in Q3 2024.
330 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.